NAVAL-1: a phase 2 trial of nanatinostat with valganciclovir in Epstein-Barr Virus-Positive relapsed and refractory lymphomas

A phase 2 trial testing nanatinostat and valganciclovir in people with relapsed and refractory Epstein-Barr virus-positive (EBV+) lymphomas.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05011058

Trial aim and background 

The aim of this trial is to find out how effective the treatment nanatinostat is when given in combination with valganciclovir in adults with EBV+ lymphomas that have either come back (relapsed) or not responded to previous treatment (refractory).

Who can enter

Adults with EBV+ lymphomas including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL) and post-transplant lymphoproliferative disorder(PTLD).

Locations

Recruitment is taking place in the following UK locations:

  • The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral
  • University College London Hospitals NHS Foundation Trust, London
  • The Christie NHS Foundation Trust, Manchester
  • Kings College Hospital, London

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05011058 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.